March 3, 2026Open Access

Clinical outcome and tolerability of DS-8201 in patients with advanced HER2-positive breast cancer: a retrospective study

Key Points

DS-8201 demonstrated significantly better efficacy compared to treatment of physician's choice (TPC).
Patients with T-DM1-pretreated HER2-positive advanced breast cancer showed similar overall safety.
Observational analysis compared DS-8201 to TPC in HER2-positive patients with advanced disease.
Findings support the clinical use of DS-8201 as a promising therapeutic option for advanced breast cancer.

Abstract

DS-8201 showed significantly better efficacy and similar overall safety compared to TPC in patients with T-DM1-pretreated HER2-positive advanced breast cancer, supporting its use as a treatment option in this setting.

Clinical outcome and tolerability of DS-8201 in patients with advanced HER2-positive breast cancer: a retrospective study

Key Points

Abstract

Cite This Study